Patent · US Active

TLR7/8 antagonists and uses thereof

US10793553B2 · kind B2 · utility

2Cited by

1References

17Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Brian A. Sherer · Nashua, US
Nadia Brugger · Cambridge, US
Ruoxi Lan · Waltham, US
Xiaoling Chen · Sharon, US

Key dates

Filing date	Jul 17, 2018
Grant date	Oct 6, 2020
Priority date	—
Expiry date	Jul 17, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.